52808 Guselkumab improves perceived stigmatization in moderate-to-severe psoriasis patients, including obese patients and patients with short disease duration: Results from the real-life G-EPOSS study until Week 76 - 01/09/24
Doi : 10.1016/j.jaad.2024.07.887
Le texte complet de cet article est disponible en PDF.
| Commercial Support: Sascha Gerdes was an advisor and/or received speakers’ honoraria and/or received grants and/or participated in clinical trials of the following companies: AbbVie, Affibody AB, Akari Therapeutics Plc, Almirall-Hermal, Amgen, AnaptysBio, Argenx BV, AstraZen. |
© 2024
Publié par Elsevier Masson SAS.
Vol 91 - N° 3S
P. AB223 - septembre 2024 Retour au numéro
Article précédent
- 53723 Guselkumab improves moderate-to-severe psoriasis and patient satisfaction leading to high patient benefit in a real-life setting: Results from the G-EPOSS study through Week 76
- Sascha Gerdes, Sebastian Zimmer, Andreas Schwinn, Rolf Ostendorf, Simmy Jacobsen, Judita Makuc, Nina Trenkler, Juliane Behrens, Sarah Tabori, Dariusch Mortazawi
- 53711 Guselkumab induction therapy is effective, safe and long lasting in mild psoriasis patients, results from a randomized, placebo-controlled exploratory trial
- Robert Rissmann, Jannik Rousel, Menthe Bergmans, Laura van der Meulen, Marieke de Kam, Joke Bouwstra, Marieke Seyger, Juul van den Reek, Naomi Klarenbeek, Tessa Niemeyer-van der Kolk, Martijn van Doorn
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?